Trial · NCT01919801
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Meeting Discharge Criteria (TMDC) | Icatibant 30 mg | 4.03 | Inter-Quartile Range 2.03 to 6.00 | days | |
| Time to Meeting Discharge Criteria (TMDC) | Placebo | 4.00 | Inter-Quartile Range 1.03 to 6.00 | days | |
| Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs) | Icatibant 30 mg | Participants with TEAEs | 27 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs) | Placebo | Participants with TEAEs | 21 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs) | Icatibant 30 mg | Participants with TESAEs | 2 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs) | Placebo | Participants with TESAEs | 1 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Icatibant 30 mg | Erythema | 31 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Placebo | Erythema | 13 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Icatibant 30 mg | Swelling | 17 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Placebo | Swelling | 13 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Icatibant 30 mg | Cutaneous pain | 10 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Placebo | Cutaneous pain | 7 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Icatibant 30 mg | Burning sensation | 15 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Placebo | Burning sensation | 7 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Icatibant 30 mg | Itching | 13 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Placebo | Itching | 6 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Icatibant 30 mg | Warm sensation | 16 | participants | |
| Number of Participants With Treatment Emergent Injection Site Reaction | Placebo | Warm sensation | 8 | participants | |
| Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination | Icatibant 30 mg | 0 | participants | ||
| Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination | Placebo | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01919801/results